汇宇制药：自愿披露HYP-6589片联合用药获得药物临床试验申请受理通知书的公告

Core Points - Sichuan Huiyu Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of HYP-6589 tablets, which are intended for use in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [2] Group 1 - The clinical trial application for HYP-6589 tablets has been accepted, indicating progress in the drug development process [2] - The project research code for HYP-6589 is "HY-0006," highlighting its identification within the company's pipeline [2] - The announcement emphasizes the lengthy drug development cycle and multiple approval stages, which may be influenced by various uncertainties [2]